HOMA-IR and Insulin Resistance: How to Interpret the Number

HOMA-IR looks more sophisticated than it is.

It takes two familiar laboratory measurements, fasting glucose and fasting insulin, and puts them together.

That simple calculation can be useful because glucose and insulin do not always become abnormal at the same time.

A person may maintain a normal fasting glucose because the pancreas is producing more insulin than it once needed. HOMA-IR helps make that relationship visible.

For the broader clinical picture, see Metabolic Health and Insulin Resistance: A Longevity Medicine Guide.

What HOMA-IR Actually Measures

HOMA stands for Homeostatic Model Assessment. The original model was developed in the 1980s to estimate insulin resistance and pancreatic beta-cell function from fasting glucose and insulin concentrations.

HOMA-IR does not directly measure how responsive muscle, liver, and other tissues are to insulin. It estimates insulin resistance from what is happening in the fasting state.

When insulin sensitivity is good, relatively modest amounts of insulin are generally sufficient to maintain fasting glucose.

As insulin resistance develops, the pancreas often compensates by producing more insulin. Fasting glucose may remain well controlled, but fasting insulin rises. Because HOMA-IR incorporates both values, the calculated result rises as well.

This compensated stage is one reason metabolic dysfunction can be present before someone meets the laboratory criteria for prediabetes or diabetes.

How HOMA-IR Is Calculated

The commonly used HOMA-IR calculation depends on the units used by the laboratory.

When glucose is reported in mg/dL:

HOMA-IR = fasting insulin (µU/mL) × fasting glucose (mg/dL) ÷ 405

When glucose is reported in mmol/L:

HOMA-IR = fasting insulin (µU/mL) × fasting glucose (mmol/L) ÷ 22.5

For example, a fasting glucose of 90 mg/dL and fasting insulin of 5 µU/mL produce a HOMA-IR of approximately 1.1.

A fasting glucose of 90 with an insulin of 15 produces a HOMA-IR of approximately 3.3.

The glucose is identical. The amount of insulin being used to maintain that glucose is not.

What Is a Normal HOMA-IR?

This is where HOMA-IR is often oversimplified.

There is no universally accepted HOMA-IR cutoff for insulin resistance.

Different studies have produced different thresholds because HOMA-IR distributions vary by population. Age, sex, ethnicity, body composition, glucose tolerance, and laboratory methodology can all influence the result.

Recent studies illustrate the problem. A 2025 analysis from the ARIC cohort found thresholds associated with future type 2 diabetes generally ranging from approximately 2.4 to 3.2 in women and 2.8 to 3.2 in men. A separate 2025 Qatar Biobank analysis identified a HOMA-IR threshold of approximately 1.9 in its study population.

Neither number should be turned into a universal rule.

You will often see HOMA-IR values below 2 described as optimal and values above 2.5 or 3 described as insulin resistant. Those ranges can be useful as rough clinical context, but they are not standardized diagnostic criteria.

We pay more attention to the entire pattern and to the direction of change over time.

Why the Insulin Result Matters So Much

In people without diabetes, fasting glucose tends to remain within a relatively narrow range. Fasting insulin can vary much more.

As a result, changes in HOMA-IR are often driven substantially by changes in fasting insulin.

This is not a weakness of the calculation. It is important to understand what the number represents.

Research comparing fasting insulin with HOMA-IR has found the two to be very highly correlated in people without diabetes. HOMA-IR should therefore not be viewed as an entirely separate metabolic test that provides information unrelated to fasting insulin.

It gives fasting insulin additional context by incorporating fasting glucose.

Read Fasting Insulin and Metabolic Health for a deeper discussion of the insulin measurement itself.

Normal Glucose Can Coexist With a High HOMA-IR

This is one of the most useful clinical patterns to recognize.

Imagine two people with a fasting glucose of 92 mg/dL.

One has a fasting insulin of 4 µU/mL. The other has a fasting insulin of 18.

The glucose result alone makes them look remarkably similar.

They are not metabolically identical.

The second person's pancreas is producing far more insulin in the fasting state to maintain approximately the same glucose concentration.

This compensatory hyperinsulinemia can precede worsening fasting glucose and A1c.

It is one reason a metabolic assessment should not automatically stop when the glucose result falls inside the laboratory reference range.

HOMA-IR Does Not Diagnose Diabetes

HOMA-IR is not part of the diagnostic criteria for diabetes.

The 2026 American Diabetes Association Standards of Care continue to diagnose diabetes using A1c and plasma glucose criteria. These include fasting plasma glucose, the two-hour glucose result during a 75-gram oral glucose tolerance test, and random plasma glucose in the appropriate clinical setting.

HOMA-IR answers a different question.

It is used to estimate insulin resistance, particularly in the fasting state. Someone can have an elevated HOMA-IR without diabetes, and someone with abnormal glucose regulation can have limitations in the way HOMA-IR reflects their insulin physiology.

What HOMA-IR Can Miss

HOMA-IR is based entirely on fasting measurements.

That makes it particularly useful for evaluating basal glucose-insulin physiology, but it does not tell us what happens after a meal or glucose challenge.

Some people maintain relatively normal fasting insulin and glucose while showing abnormal glucose disposal or insulin responses after eating. Studies comparing fasting HOMA-IR with oral glucose tolerance testing and clamp measurements have demonstrated that fasting measures can miss this pattern.

A normal HOMA-IR therefore does not prove that insulin sensitivity is normal in every tissue or under every metabolic condition.

When the history strongly suggests metabolic dysfunction despite reassuring fasting measurements, additional testing may be appropriate.

HOMA-IR Is Not a Direct Measurement of Insulin Sensitivity

The hyperinsulinemic-euglycemic clamp is generally considered the research reference method for measuring insulin sensitivity.

It is also labor intensive, time consuming, and impractical for routine clinical medicine.

HOMA-IR is one of several surrogate measures developed to provide useful information without requiring that level of testing.

That distinction matters when interpreting the result. HOMA-IR is an estimate. It should not be presented with more precision than the method can support.

A result of 2.6 is not meaningfully transformed into a diagnosis simply because someone else measured 2.4.

One HOMA-IR Result Can Move More Than People Realize

Insulin has meaningful biological variability.

The European Biological Variation Study measured fasting glucose and insulin repeatedly in people without diabetes and found within-person variation in HOMA-IR of approximately 27 percent.

This is another reason not to overinterpret a small change between two laboratory results.

Sleep, recent exercise, acute illness, stress, alcohol, food intake before the fasting period, medications, and normal biological variation can all influence insulin and glucose.

A substantial change that persists under similar testing conditions is more meaningful than a small movement in one isolated result.

The Laboratory Matters

Glucose testing is relatively standardized. Insulin testing is less uniform.

Commercial insulin assays can produce different results from the same underlying sample. Because fasting insulin is part of the HOMA-IR equation, those differences carry directly into the HOMA-IR result.

This becomes particularly important when someone is comparing results from different laboratories or trying to follow a small change over time.

When possible, using the same laboratory and similar fasting conditions makes longitudinal interpretation more useful.

HOMA1 and HOMA2 Are Not the Same Calculation

The familiar formula using glucose and insulin is generally referred to as the original HOMA model or HOMA1.

A later computer-based model, HOMA2, was developed to account for more of the nonlinear physiology involved in insulin and glucose regulation. The University of Oxford Diabetes Trials Unit maintains the HOMA2 calculator.

HOMA1 and HOMA2 results should not simply be treated as interchangeable numbers.

For routine clinical discussions, most people referring to a calculated HOMA-IR are using the original fasting insulin × fasting glucose formula unless otherwise specified.

HOMA-IR and the Triglyceride-to-HDL Pattern

Insulin resistance frequently changes lipid metabolism as well as glucose regulation.

The liver may produce more triglyceride-rich VLDL particles. Triglycerides rise, HDL may fall, and the composition of LDL particles can change.

A rising HOMA-IR accompanied by rising triglycerides and falling HDL is a very different metabolic pattern from an isolated HOMA-IR result with otherwise stable markers.

The triglyceride-to-HDL ratio can provide another inexpensive clue to insulin-resistant lipid metabolism.

It does not replace HOMA-IR, and HOMA-IR does not replace the lipid panel.

Read Triglyceride-to-HDL Ratio and Metabolic Health.

Where ApoB Fits

Insulin resistance can increase the number of triglyceride-rich and cholesterol-depleted ApoB-containing particles in circulation.

This is one reason LDL-C sometimes underestimates atherogenic particle burden in people with metabolic dysfunction.

HOMA-IR and ApoB describe different parts of the physiology.

HOMA-IR estimates insulin resistance. ApoB estimates the number of circulating atherogenic lipoprotein particles.

When both are elevated, we are looking at evidence of metabolic dysfunction alongside increased atherogenic particle exposure.

When they do not move together, that is useful information too.

Learn more in ApoB vs LDL-C: What Actually Matters?.

Visceral Fat and Body Composition

Insulin resistance is closely associated with visceral fat, but body weight alone cannot tell us how much visceral fat someone carries.

Two people can have the same weight and BMI with very different proportions of muscle, subcutaneous fat, and abdominal visceral fat.

A rising HOMA-IR often becomes more understandable when we can see the accompanying change in body composition.

DEXA and SECA testing can help quantify fat mass, lean mass, and visceral fat rather than relying entirely on the scale.

Skeletal muscle is important as well. Muscle is a major site of insulin-stimulated glucose disposal, making the preservation of lean mass particularly important as people age and during weight loss.

Explore Body Composition and Longevity Medicine.

HOMA-IR and Fatty Liver

Insulin resistance and metabolic-associated steatotic liver disease frequently occur together.

The liver plays a central role in fasting glucose and lipid regulation. Hepatic insulin resistance can contribute to increased glucose production, higher VLDL output, elevated triglycerides, and worsening metabolic control.

Higher HOMA-IR values are commonly found in people with fatty liver, although HOMA-IR cannot diagnose liver fat or determine its severity.

Normal ALT and AST values also do not completely exclude metabolic liver disease.

When the metabolic pattern raises concern, liver enzymes, triglycerides, glucose regulation, body composition, clinical history, and imaging may all contribute useful information.

Sleep and Insulin Resistance

Metabolic health is not determined by diet alone.

Short sleep, circadian disruption, untreated sleep apnea, chronic stress, and physical inactivity can all impair glucose regulation and insulin sensitivity.

Sleep apnea deserves particular attention because it commonly travels with visceral fat, hypertension, insulin resistance, and cardiovascular disease.

A person can make considerable dietary changes and still struggle metabolically if severe sleep-disordered breathing remains untreated.

Explore Sleep and Recovery in Longevity Medicine.

Menopause and Midlife Metabolic Change

Many women notice a change in body composition and glucose regulation during the menopause transition.

Changes in estrogen signaling occur alongside changes in sleep, muscle mass, activity, appetite, and fat distribution. Visceral fat may increase even when the number on the scale does not change dramatically.

HOMA-IR can be useful in this setting because it allows glucose and insulin to be considered together.

It should not be used to attribute every metabolic change to hormones. It can help identify whether insulin resistance is becoming part of the midlife picture.

See Hormone Transitions and Longevity Medicine.

HOMA-IR and Cardiovascular Risk

Insulin resistance rarely travels alone.

It commonly clusters with hypertension, visceral fat, elevated triglycerides, fatty liver, inflammatory changes, and atherogenic dyslipidemia.

A large systematic review and meta-analysis involving more than 200,000 participants found that higher HOMA-IR was associated with greater subsequent risk of type 2 diabetes, hypertension, and nonfatal major cardiovascular events.

HOMA-IR is not a cardiovascular risk score, and it should not replace ApoB, Lp(a), blood pressure, smoking history, kidney function, family history, or cardiovascular imaging when those are clinically relevant.

It adds metabolic information to that assessment.

Explore Preventive Cardiology and Cardiometabolic Health.

The Brain–Metabolic Connection

Systemic insulin resistance has also become part of the discussion around cognitive aging.

Insulin has important functions in the brain, including roles in energy regulation and neuronal signaling. Epidemiologic research has linked insulin resistance and metabolic disease with higher risk of cognitive decline and dementia.

HOMA-IR does not measure insulin resistance inside the brain, and an elevated HOMA-IR should not be interpreted as a diagnosis of “brain insulin resistance.”

It tells us that systemic insulin regulation deserves attention.

Related reading: Fasting Insulin and Brain Health.

How We Use HOMA-IR at HormoneSynergy®

We do not treat HOMA-IR as an isolated score.

Depending on the patient, we may consider it alongside:

• Fasting insulin
• Fasting glucose
• Hemoglobin A1c
• Triglycerides and HDL
• ApoB and non-HDL cholesterol
• Lipoprotein(a)
• Liver enzymes and liver health
• Blood pressure
• Waist circumference
• DEXA or SECA body composition
• Visceral fat
• Skeletal muscle mass
• Sleep and possible sleep apnea
• Exercise and cardiorespiratory fitness
• Nutrition and alcohol intake
• Medications
• Hormone status when clinically relevant
• Personal and family cardiovascular history

The number becomes useful when it helps explain the patient.

A rising HOMA-IR accompanied by increasing visceral fat, higher triglycerides, and worsening blood pressure deserves attention even if glucose remains technically normal.

An unexpected single result in an otherwise stable metabolic picture may deserve confirmation before conclusions are drawn.

Improving HOMA-IR Means Improving the Underlying Physiology

HOMA-IR is a marker. It is not the disease itself.

When insulin resistance is present, treatment should address what is driving it.

For many people that includes regular resistance training, aerobic activity, preservation or gain of muscle, reduction of excess visceral fat, improved food quality, adequate protein and fiber, better sleep, treatment of sleep apnea when present, and reducing excess alcohol.

Weight loss can substantially improve insulin sensitivity when excess adiposity is contributing to the problem. The goal is not simply to make the scale move. Preserving skeletal muscle and reducing visceral fat are particularly important.

Medication may also be appropriate depending on the underlying condition, degree of metabolic dysfunction, cardiovascular risk, and other clinical factors.

The treatment decision should never be based on a HOMA-IR number alone.

Frequently Asked Questions

What is HOMA-IR?

HOMA-IR is a calculated estimate of insulin resistance derived from fasting glucose and fasting insulin.

How is HOMA-IR calculated?

When glucose is measured in mg/dL, HOMA-IR is calculated as fasting insulin multiplied by fasting glucose and divided by 405. When glucose is measured in mmol/L, the denominator is 22.5.

What is a normal HOMA-IR?

There is no universally accepted cutoff. Research thresholds vary substantially among populations, laboratories, sexes, and ethnic groups. Lower values generally reflect greater insulin sensitivity, but interpretation should include fasting insulin, glucose, body composition, lipids, and the rest of the clinical picture.

Is a HOMA-IR below 2 considered optimal?

Values below approximately 2 are frequently described as metabolically favorable, but 2.0 is not a universal medical cutoff. Published thresholds for insulin resistance vary considerably by population and methodology.

Can HOMA-IR be elevated while glucose is normal?

Yes. The pancreas can compensate for insulin resistance by producing more insulin, allowing fasting glucose to remain normal despite a higher insulin requirement.

Can HOMA-IR be normal even if someone has insulin resistance?

Yes. HOMA-IR is based on fasting measurements and may not identify every form of insulin resistance, particularly abnormalities that become more apparent after eating or during an oral glucose tolerance test.

Is HOMA-IR used to diagnose diabetes?

No. Diabetes is diagnosed using established A1c and plasma glucose criteria. HOMA-IR is a surrogate estimate of insulin resistance.

Is HOMA-IR better than fasting insulin?

Not necessarily. The two measurements are closely related, particularly in people whose fasting glucose remains within a narrow range. HOMA-IR provides additional context by considering fasting glucose and insulin together.

What is the difference between HOMA1 and HOMA2?

HOMA1 refers to the original model and commonly used fasting glucose and insulin formula. HOMA2 is a later computer-based model developed to account for more of the nonlinear physiology of glucose and insulin regulation.

Should HOMA-IR be repeated?

An unexpected result may be worth confirming because insulin and HOMA-IR have meaningful biological variability. Trends obtained under reasonably similar fasting and laboratory conditions are generally more informative than small differences between isolated results.

References

• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495.
• Decaro-Fragoso MC, et al. Determining Insulin Resistance Cutoffs in Mexican Adults: Percentile Distribution vs. Receiver Operating Characteristic Curve Analysis. 2025. PMID: 40161122.
• Aliyu U, et al. Evaluating indices of insulin resistance and estimating the prevalence of insulin resistance in a large biobank cohort. Frontiers in Endocrinology. 2025;16:1591677. PMID: 40421243.
• Sex-specific optimal cut-off points for metabolic health indicators to predict incident type 2 diabetes mellitus. 2025. PMID: 40087045.
• Carobene A, et al. The biological variation of insulin resistance markers: data from the European Biological Variation Study (EuBIVAS). 2024. PMID: 38987271.
• American Diabetes Association Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
• HOMA2 Calculator. University of Oxford Diabetes Trials Unit.

Editorial Note

This article is part of the HormoneSynergy® longevity medicine education library. It is intended for general education and does not replace individualized medical care. HOMA-IR, fasting insulin, glucose, and other metabolic markers should be interpreted in the context of laboratory methodology, medical history, medications, body composition, lifestyle, and other relevant clinical findings.